Skip to main content

Zepbound News (Page 8)

FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions

ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...

FDA Approves Zepbound (tirzepatide) for Chronic Weight Management

INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity t...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Weight Loss (Obesity / Overweight), Obstructive Sleep Apnea/Hypopnea Syndrome

Zepbound patient information at Drugs.com